Lab
Ohana Genetics INC
Ohana Genetics INC was paid $22K by Medicaid between May 2019 and Apr 2024, across 13 billing codes. Its largest line is 87798, Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism — 62% of everything it billed.
33Billing provider infoOHANA GENETICS INC
HONOLULU, HI 96814
HONOLULU, HI 96814
33aNPI1225326028assigned 07/13/2011
33bProvider typeClinical Medical Laboratory
28Total paid$22K
24GClaims1,779
24DCodes billed13
24AFirst – last monthMay 2019 – Apr 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Hawaii
Rank by total paid#13 of 18
Median peer was paid$163K
This provider vs. median0.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 1,426 | $0.00 | |
| 2023 | 188 | $13K | |
| 2024incomplete | 165 | $9K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 62% | 110 | 65 | $14K |
| 87481 | 13% | 56 | 52 | $3K | |
| 87653 | 6.4% | 52 | 48 | $1K | |
| 87529 | 4.3% | 27 | 27 | $967.91 | |
| 87511 | 3.7% | 24 | 24 | $824.16 | |
| 87625 | 2.0% | 12 | 12 | $456.30 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.8% | 12 | 12 | $407.44 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.8% | 12 | 12 | $407.44 |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 1.7% | 12 | 12 | $387.84 |
| 87640 | 1.4% | 18 | 14 | $306.49 | |
| 87563 | 1.4% | 18 | 16 | $303.12 | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 0% | 1,303 | 1,136 | $0.00 |
1 more codes
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 0% | 123 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDEL SIGNORE, JOSEPH (OWNER)
| Provider | Location | Paid |
|---|---|---|
| Nextgen Laboratories, INC. | Newport Beach, CA | $7.65M |
| Diagnostic Laboratory Solutions | Dallas, TX | $12K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.